Difluprednate Emulsion
Product Images NDC 46708-750

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Difluprednate (NDC 46708-750). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Difluprednate-bottle-label-ltd (Difluprednate Bottle Label Ltd)

Contains dilprednate 0.05% for ophthalmic use, manufactured by Alembic Pharmaceuticals Limited in Gujarat, India. This sterile emulsion comes in a 5mL packaging. Refer to the package insert for usual dosage and storage instructions. This is a prescription-only medication.*

FDA Label Image

Difluprednate-carton-limited (Difluprednate Carton Limited)

This is a description of Difluprednate Ophthalmic Emulsion 0.05% manufactured by Alembic Pharmaceuticals Limited in India. The product is sterile and suitable for topical eye use only. Each mL contains 0.05mg of difluprednate along with other inactive ingredients. It is stored at temperatures between 20°C to 25°C and should be protected from light. The preservative used is 0.1% sorbic acid. Once opened, the emulsion can be used until the expiration date indicated on the bottle. It is essential to keep it out of reach of children and refer to the package insert for the usual dosage instructions.*

FDA Label Image

Difluprednate-figure-1 (Difluprednate Figure 1)

This text provides data on the percentage of subjects with clear anterior chamber cells (cell count = 0) after receiving Difluprednate ophthalmic emulsion four times a day from day 8 to day 15. The results show that 2% of subjects had clear cells on day 8, and this increased to 12% by day 15. Additionally, there is a note indicating statistical significance with *P<0.05 when comparing the treatment group (n=107) with the placebo group (n=220).*

FDA Label Image

Difluprednate-figure-2 (Difluprednate Figure 2)

This information presents data on the percent of subjects who were pain free during the observation period. The table indicates the values for different time points - Day 3, Day 8, and Day 15. It compares the efficacy of difluprednate ophthalmic emulsion used four times a day (QID) to a placebo. The results suggest that the use of difluprednate ophthalmic emulsion led to a statistically significant improvement in pain relief compared to the placebo.*

FDA Label Image

Difluprednate-structure (Difluprednate Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.